Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

30.53USD
17 Feb 2017
Change (% chg)

$0.02 (+0.07%)
Prev Close
$30.51
Open
$30.39
Day's High
$30.55
Day's Low
$30.29
Volume
570,121
Avg. Vol
1,264,165
52-wk High
$33.77
52-wk Low
$25.25

RHHBY.PK

Chart for RHHBY.PK

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $210,984.59
Shares Outstanding(Mil.): 6,900.50
Dividend: 1.02
Yield (%): 3.34

Financials

  RHHBY.PK Industry Sector
P/E (TTM): 21.99 28.47 29.39
EPS (TTM): 1.39 -- --
ROI: 19.20 13.57 13.06
ROE: 42.66 14.45 14.19

BRIEF-Roche Diabetes Care signs exclusive agreement with Medtronic

* Roche Diabetes Care signs exclusive agreement with Medtronic for bluetooth enabled blood glucose meters Further company coverage: (Reporting by Zurich Newsroom)

Feb 15 2017

BRIEF-Roche Holding discloses 5.6 pct passive stake in Avexis as of Dec 31- SEC Filing

* Roche Holding Ltd discloses 5.6 percent passive stake in Avexis Inc as of December 31, 2016 - SEC Filing Source text: [http://bit.ly/2llxGXX] Further company coverage:

Feb 07 2017

BRIEF-Roche Holding reports 8.5pct passive stake in Senseonics Holdings as of Dec 31 - SEC Filing

* Roche Holding Ltd reports 8.5% passive stake in Senseonics Holdings Inc as of December 31, 2016 - SEC Filing Source text: [http://bit.ly/2lhzCEQ] Further company coverage:

Feb 07 2017

BRIEF-Roche Canada says Health Canada approves Gazyva

* Roche Canada - Health Canada approves Gazyva for patients with previously treated follicular lymphoma Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-Roche's Herceptin approved in subcutaneous form in Switzerland

* Roche media release: subcutaneous formulation of roche's herceptin approved in switzerland for the treatment of her2-positive breast cancer Source text for Eikon: Further company coverage: (Reporting by John Miller)

Feb 06 2017

BRIEF-Roche confirms 2017 guidance irrespective of aphinity trial outcome

* Ceo says confirms 2017 guidance irrespective of outcome of aphinity trial Source text for Eikon: Further company coverage: (Reporting by John Miller)

Feb 01 2017

Roche wants to expand diabetes business, not sell it

ZURICH Roche is looking to expand its $2 billion-per-year diabetes business, not sell it or spin it off.

Feb 01 2017

BRIEF-Roche expects Tamiflu sales in 2017 to drop following patent expiry

* Ceo says sees no "direction change" in attractiveness of u.s. Market under president trump

Feb 01 2017

UPDATE 1-Roche wants to expand diabetes business, not sell it

ZURICH, Feb 1 Roche is looking to expand its $2 billion-per-year diabetes business, not sell it or spin it off.

Feb 01 2017

Competition stalls Roche margin growth; drugmaker commits to diabetes unit

ZURICH Roche on Wednesday said competition and spending on new drugs would likely stall its margin growth in 2017 as the Swiss drugmaker grapples with patent expirations of some blockbuster medicines that will expose them to competition.

Feb 01 2017

More From Around the Web

Earnings vs. Estimates